Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novolizer: a multidose dry powder inhaler.

Caroline Fenton1, Gillian M Keating, Greg L Plosker

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 12, 2003
PubMed
Summary

The Novolizer dry powder inhaler effectively delivers asthma medications like salbutamol and budesonide, demonstrating good patient use and comparable efficacy to other inhalers. It showed improved compliance and was preferred by most patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management.

Drugs & therapy perspectives : for rational drug selection and use·2023
Same author

Antidepressants with anti-inflammatory properties may be useful in long COVID depression.

Drugs & therapy perspectives : for rational drug selection and use·2022
Same author

mRNA COVID-19 vaccines are well tolerated and myopericarditis is a rare adverse event following immunisation.

Drugs & therapy perspectives : for rational drug selection and use·2022
Same author

Emerging small molecule antivirals may fit neatly into COVID-19 treatment.

Drugs & therapy perspectives : for rational drug selection and use·2022
Same author

COVID-19: State of the Vaccination.

Drugs & therapy perspectives : for rational drug selection and use·2021
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Medical Devices

Background:

  • The Novolizer is a multidose, breath-actuated dry powder inhaler (DPI) for salbutamol and budesonide.
  • It features patient feedback mechanisms and an inspiratory flow rate threshold for optimized dosing.

Purpose of the Study:

  • To evaluate the usability, lung deposition, and clinical efficacy of the Novolizer inhaler in patients with asthma and chronic obstructive pulmonary disease (COPD).

Main Methods:

  • Studies involved children and adults with asthma and patients with COPD.
  • Methods included assessing peak inspiratory flow rates (PIFRs), lung deposition of budesonide, and forced expiratory volume in 1 second (FEV(1)) changes.
  • Comparisons were made against pressurized metered-dose inhalers (MDIs) and another DPI (Turbuhaler).

Main Results:

  • Children (4-11 years) with asthma correctly used Novolizer, generating PIFRs well above the device threshold.
  • Median lung deposition of budesonide was 19.9-32.1% in healthy volunteers.
  • Novolizer showed comparable FEV(1) improvements to Sultanol MDI for salbutamol in COPD and asthma patients.
  • Equivalent FEV(1) and symptom improvements were observed with Novolizer and Turbuhaler for budesonide in asthma patients.
  • Physicians noted improved compliance in 80% of asthma patients using Novolizer.

Conclusions:

  • Novolizer is a well-accepted DPI with effective drug delivery and comparable clinical outcomes to other inhaler devices.
  • It demonstrates good usability in pediatric and adult populations and may improve patient compliance.

Related Experiment Videos